Kliniske retningslinier for udredning af cancer thyroidear 2009, udkast

Thyreoideacancer – udkast Kliniske retningslinier – revision – juni 2009
in patients with differentiated thyroid carcinoma. J.Clin.Endocrinol.Metab 1998;83:1121-7.
169. Spencer CA, Bergoglio LM, Kazarosyan M, Fatemi S, LoPresti JS. Clinical impact of thyroglobulin
(Tg) and Tg autoantibody method differences on the management of patients with differentiated thyroid
carcinomas. J.Clin.Endocrinol.Metab 2005;90:5566-75.
170. Clark OH. TSH suppression in the management of thyroid nodules and thyroid cancer. World J.Surg.
1981;5:39-47.
171. Cooper DS, Specker B, Ho M, Sperling M, Ladenson PW, Ross DS et al. Thyrotropin suppression and
disease progression in patients with differentiated thyroid cancer: results from the National Thyroid
Cancer Treatment Cooperative Registry. Thyroid 1998;8:737-44.
172. Schlumberger M, Pacini F. Local and regional recurrences. In: Schlumberger M, Pacini F. Thyroid
tumors, Second ed. Paris: Éditions Nucléon, 2003:181-92.
173. British Thyroid Association and Royal College of Physicians. Guidelines for the mamagement og thyroid
cancer, Second edition. www.british-thyroid-association.org/guidelines.htm . 2007.
Ref Type: Internet Communication
174. Hay ID. Papillary thyroid carcinoma. In: Hay ID, Wass JA. Clinical endocrine oncology, Second Edition
ed. Massachusetts: Blackwell Publishing, 2008:130-42.
175. Shah MH, Ringel MD. Follicular thyroid carcinoma. In: Hay ID, Wass JA. Clinical endocrine oncology,
Second Edition ed. Massachusetts: Blackwell Publishing, 2008:130-42.
176. DeGroot LJ, Kaplan EL, Shukla MS, Salti G, Straus FH. Morbidity and mortality in follicular thyroid
cancer. J Clin Endocrinol.Metab 1995;80:2946-53.
177. Simon D, Goretzki PE, Witte J, Roher HD. Incidence of regional recurrence guiding radicality in differentiated
thyroid carcinoma. World J Surg. 1996;20:860-6.
178. Witte J, Goretzki PE, Dieken J, Simon D, Roher HD. Importance of lymph node metastases in follicular
thyroid cancer. World J Surg. 2002;26:1017-22.
179. Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and
follicular thyroid cancer. Am.J Med. 1994;97:418-28.
180. Roh JL, Park JY, Rha KS, Park CI. Is central neck dissection necessary for the treatment of lateral cervical
nodal recurrence of papillary thyroid carcinoma? Head Neck 2007;29:901-6.
181. Farrag TY, Agrawal N, Sheth S, Bettegowda C, Ewertz M, Kim M et al. Algorithm for safe and effective
reoperative thyroid bed surgery for recurrent/persistent papillary thyroid carcinoma. Head Neck
2007;29:1069-74.
182. Kloos RT, Mazzaferri EL. A single recombinant human thyrotropin-stimulated serum thyroglobulin
measurement predicts differentiated thyroid carcinoma metastases three to five years later.
J.Clin.Endocrinol.Metab 2005;90:5047-57.
183. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ et al. Management guidelines for
patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2006;16:109-42.
184. Monchik JM, DeLellis RA. Re-operative neck surgery for well-differentiated thyroid cancer of follicular
origin. J.Surg.Oncol 2006;94:714-8.
185. Khandelwal S, Sener SF, Purdy L, Perlman RM. I-123-guided excision of metastatic papillary thyroid
63